Related Experiment Video
Updated: Dec 6, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
Tama Dinur1, Majdolen Istaiti1, Dafna Frydman1
1Gaucher Unit, Shaare Zedek Medical Centre, P.O. Box 3235, 91031, Jerusalem, Israel.
Background:
It is now acknowledged that the input of patients in health outcome assessment is vital to understanding the impact of diseases and interventions for those diseases. This study is the first report of patient-reported outcome measures (PROM) in a large cohort of patients with type 1 Gaucher disease (GD1) enabling us to study predictors of the reported outcomes.
Method:
The PROM was sent via a mobile phone survey to 405 adult patients with GD1. Demographics, clinical data, and treatment status were extracted from clinic charts. Age, sex, severity score index (SSI) at presentation and treatment status were used as variables to assess outcomes.
Results:
A total of 192 patients with GD1 (111 females) responded (47.4% response rate), of whom 124 (64.5%) had received GD1-specific therapy. Around 40% of patients reported that GD had restricted their education/job and fun activities and were concerned about being emotional and financial burdens on others. Concerns regarding the risk of bone disease and Parkinson disease were also high (60%). The severity of GD1 (reflected by the need for GD1-specific therapy and a high SSI) was associated with GD1-related restrictions and concerns, fatigue, physical weakness, bone pain, and worry regarding the future.
Conclusions:
The use of GD1 specific PROM highlights personal problems that are not captured by traditional outcome parameters and that need to be addressed to improve health-related quality of life. Validated PROM should be included among the outcome measures in clinical practice and future prospective studies for patients with chronic and rare diseases.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Chronic Pancreatitis II: Collaborative Care
Assessment:
Therapeutic Drug Monitoring: Affecting Factors
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Measurement of Bioavailability: Pharmacodynamic Methods
Drug Product Performance: In Vitro–In Vivo Correlation

